Holen Sie sich die Stockscreener-App
1.98
2.94%
-0.06
Handel nachbörslich:
2.00
0.02
+1.01%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt IOVA?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$2.04
Offen:
$2.07
24-Stunden-Volumen:
11.20M
Relative Volume:
0.88
Marktkapitalisierung:
$794.76M
Einnahmen:
$32.77M
Nettoeinkommen (Verlust:
$-440.22M
KGV:
-1.1856
EPS:
-1.67
Netto-Cashflow:
$-400.48M
1W Leistung:
-11.61%
1M Leistung:
+3.66%
6M Leistung:
-73.17%
1J Leistung:
-75.16%
1-Tages-Spanne:
$1.97
$2.088
1-Wochen-Bereich:
$1.95
$2.22
52-Wochen-Spanne:
$1.6385
$12.51
Iovance Biotherapeutics Inc Stock (IOVA) Company Profile
Firmenname
Iovance Biotherapeutics Inc
Sektor
Branche
Telefon
(650) 260-7120
Adresse
825 INDUSTRIAL ROAD, SAN CARLOS
Vergleichen Sie IOVA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IOVA
Iovance Biotherapeutics Inc
|
1.98 | 794.76M | 32.77M | -440.22M | -400.48M | -1.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
440.87 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
509.72 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
309.70 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
542.15 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
247.08 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Iovance Biotherapeutics Inc Stock (IOVA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-05-16 | Herabstufung | UBS | Buy → Neutral |
| 2025-05-12 | Herabstufung | Truist | Buy → Hold |
| 2025-05-09 | Herabstufung | Citizens JMP | Mkt Outperform → Mkt Perform |
| 2024-10-24 | Eingeleitet | UBS | Buy |
| 2024-07-29 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2023-11-20 | Eingeleitet | Goldman | Buy |
| 2023-09-18 | Bestätigt | Barclays | Overweight |
| 2023-05-30 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2023-03-27 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2023-01-27 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-12-09 | Herabstufung | Goldman | Buy → Neutral |
| 2022-10-31 | Eingeleitet | Guggenheim | Neutral |
| 2022-08-18 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2022-01-28 | Hochstufung | Stifel | Hold → Buy |
| 2021-12-07 | Fortgesetzt | Cowen | Outperform |
| 2021-06-10 | Hochstufung | JMP Securities | Mkt Perform → Mkt Outperform |
| 2021-05-20 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-05-19 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2021-05-19 | Herabstufung | Stifel | Buy → Hold |
| 2021-05-03 | Eingeleitet | Truist | Buy |
| 2021-04-16 | Eingeleitet | Goldman | Buy |
| 2021-03-08 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2020-12-15 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2020-10-06 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2020-04-22 | Eingeleitet | Mizuho | Buy |
| 2020-03-04 | Eingeleitet | Barclays | Overweight |
| 2020-02-26 | Bestätigt | H.C. Wainwright | Buy |
| 2020-02-26 | Bestätigt | Oppenheimer | Outperform |
| 2019-12-18 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2019-10-01 | Eingeleitet | Stifel | Buy |
| 2019-04-29 | Eingeleitet | Piper Jaffray | Overweight |
| 2019-02-28 | Bestätigt | Chardan Capital Markets | Buy |
| 2019-02-07 | Eingeleitet | Robert W. Baird | Outperform |
| 2018-12-31 | Fortgesetzt | B. Riley FBR | Buy |
| 2018-07-06 | Bestätigt | Chardan Capital Markets | Buy |
| 2018-04-10 | Hochstufung | B. Riley FBR, Inc. | Neutral → Buy |
| 2018-03-13 | Bestätigt | B. Riley FBR, Inc. | Neutral |
| 2018-02-23 | Herabstufung | B. Riley FBR, Inc. | Buy → Neutral |
| 2018-01-25 | Bestätigt | H.C. Wainwright | Buy |
| 2017-11-01 | Bestätigt | B. Riley FBR, Inc. | Buy |
Alle ansehen
Iovance Biotherapeutics Inc Aktie (IOVA) Neueste Nachrichten
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Iovance - Bluefield Daily Telegraph
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Iovance Biotherapeutics, Inc. of Class Action Lawsuit and Upcoming DeadlinesIOVA - FinancialContent
The Gross Law Firm Notifies Shareholders of Iovance Biotherapeutics, Inc. (IOVA) of a Class ... - Bluefield Daily Telegraph
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Iovance Biotherapeutics - FinancialContent
Wealth Enhancement Advisory Services LLC Lowers Position in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) - Defense World
Iovance’s (IOVA) CFO Resigns Amid Launch Setbacks And Legal PressureHagens Berman - ACCESS Newswire
IOVANCE BIOTHERAPEUTICS SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK - Bluefield Daily Telegraph
IOVANCE BIOTHERAPEUTICS SHAREHOLDER ALERT BY FORMER - GlobeNewswire
Iovance Biotherapeutics CFO Jean-Marc Bellemin to Depart - MarketScreener
ROSEN, A LEADING LAW FIRM, Encourages Iovance - GlobeNewswire
ROSEN, A LEADING LAW FIRM, Encourages Iovance Biotherapeutics, Inc. Investors to Secure Counsel - Bluefield Daily Telegraph
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Iovance Biotherapeutics, Inc.IOVA - PR Newswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class - GlobeNewswire
IOVA SHAREHOLDER REPORT: Iovance Biotherapeutics, Inc. was - GlobeNewswire
IOVA Shareholders Have the Right to Lead the Iovance Biotherapeutics, Inc. Securities LawsuitContact the DJS Law Group to Discuss Your RightsELV - PR Newswire
IOVA Investors Have Opportunity to Lead Iovance Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm - PR Newswire
Lost Money on Iovance Biotherapeutics, Inc. (IOVA)? Contact Levi & Korsinsky Before July 14, 2025 to Join Class Action - ACCESS Newswire
Shareholders that lost money on Iovance Biotherapeutics, Inc.(IOVA) should contact The Gross Law Firm about pending Class ActionIOVA - PR Newswire
Shareholders of Iovance Biotherapeutics, Inc. (IOVA): Protect Your Rights Before July 14, 2025 – Contact Levi & Korsinsky - ACCESS Newswire
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Iovance ... - Eagle-Tribune
Levi & Korsinsky Announces the Filing of a Securities Class - GlobeNewswire
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Iovance Biotherapeutics, Inc.(IOVA) Shareholders - GlobeNewswire Inc.
Lost Money on Iovance Biotherapeutics, Inc. (IOVA)? Urged to Join Class Action Before July 14, 2025Contact Levi & Korsinsky - ACCESS Newswire
Levi & Korsinsky Notifies Iovance Biotherapeutics, Inc. (IOVA) Shareholders of Class Action Lawsuit and July 14, 2025 Deadline - ACCESS Newswire
Iovance Biotherapeutics, Inc. Sued for Securities Law ViolationsInvestors Should Contact Levi & Korsinsky for More InformationIOVA - The Victoria Advocate
ROSEN, LEADING INVESTOR COUNSEL, Encourages Iovance Biotherapeutics, Inc. Investors to Secure ... - Bluefield Daily Telegraph
ROSEN, LEADING INVESTOR COUNSEL, Encourages Iovance - GlobeNewswire
ROSEN, LEADING INVESTOR COUNSEL, Encourages Iovance Biotherapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – IOVA - TradingView
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Iovance Biotherapeutics - StreetInsider
Iovance: Amtagvi's Rocky Launch And Mounting Concerns Lead To A 'Sell' Rating - Seeking Alpha
IOVA SHAREHOLDERS: Iovance Biotherapeutics, Inc. Investors are Reminded of the Pending Securities Fraud Class Action – Contact BFA Law by July 14 Deadline (NASDAQ:IOVA) - GlobeNewswire
iovance cfo resigns to pursue new opportunities By Investing.com - Investing.com India
iovance cfo resigns to pursue new opportunities - Investing.com
Iovance Biotherapeutics IncJean-Marc Bellemin To Resign As CFO - marketscreener.com
Iovance Biotherapeutics’ SWOT analysis: TIL therapy stock faces challenges amid promise - Investing.com India
Securities Lawsuit Alert: Iovance Biotherapeutics, Inc. (IOVA)Contact Levi & Korsinsky Before July 14, 2025 - ACCESS Newswire
Shareholders of Iovance Biotherapeutics, Inc. (IOVA): Protect Your Rights Before July 14, 2025Contact Levi & Korsinsky - ACCESS Newswire
Investors who lost money on Iovance Biotherapeutics, Inc. (IOVA) should contact Levi & ... - Bluefield Daily Telegraph
Investors who lost money on Iovance Biotherapeutics, Inc. - GlobeNewswire
Deadline Alert: Iovance Biotherapeutics, Inc. (IOVA) Investors Who Lost Money Urged to Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit - GlobeNewswire
IOVA Investors Have Opportunity to Lead Iovance Biotherapeutics, Inc. Securities Fraud Lawsuit - marketscreener.com
Iovance’s (IOVA) Promising Cell Therapy Falters Triggering UBS Downgrades and Investor Lawsuit– Hagens Berman - GlobeNewswire
IOVA CLASS ACTION: Invest in Iovance Biotherapeutics, Inc.? - GlobeNewswire
Levi & Korsinsky Urges Iovance Biotherapeutics, Inc. (IOVA) Shareholders to Act Before Lead Plaintiff Deadline July 14, 2025 - ACCESS Newswire
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Iovance Biotherapeutics - GlobeNewswire
IOVA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
Iovance’s (IOVA) Promising Cell Therapy Falters Triggering UBS Downgrades and Investor LawsuitHagens Berman - ACCESS Newswire
Iovance Biotherapeutics, Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross ... - Bluefield Daily Telegraph
Iovance Biotherapeutics, Inc. (IOVA) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - PR Newswire
Shareholders that lost money on Iovance Biotherapeutics, Inc.(IOVA) Urged to Join Class ActionContact The Gross Law Firm to Learn More - The Victoria Advocate
IOVANCE BIOTHERAPEUTICS SHAREHOLDER ALERT: CLAIMSFILER - GlobeNewswire
Finanzdaten der Iovance Biotherapeutics Inc-Aktie (IOVA)
Umsatz
Nettogewinn
Free Cashflow
ENV
Iovance Biotherapeutics Inc-Aktie (IOVA) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Puri Raj K. | Chief Regulatory Officer |
Jun 02 '25 |
Option Exercise |
0.00 |
5,469 |
0 |
212,321 |
| Vogt Frederick G | Interim CEO & General Counsel |
Jun 02 '25 |
Option Exercise |
0.00 |
52,085 |
0 |
426,731 |
| GRAF FINCKENSTEIN FRIEDRICH | Chief Medical Officer |
Jun 02 '25 |
Option Exercise |
0.00 |
12,695 |
0 |
105,608 |
| BILINSKY IGOR | Chief Operating Officer |
Jun 02 '25 |
Option Exercise |
0.00 |
12,305 |
0 |
99,883 |
| Bellemin Jean-Marc | Chief Financial Officer |
Jun 02 '25 |
Option Exercise |
0.00 |
8,789 |
0 |
64,993 |
| Puri Raj K. | Chief Regulatory Officer |
May 23 '25 |
Buy |
1.74 |
5,600 |
9,743 |
206,852 |
| Vogt Frederick G | Interim CEO & General Counsel |
May 14 '25 |
Buy |
1.69 |
25,000 |
42,250 |
374,646 |
| Puri Raj K. | Chief Regulatory Officer |
Mar 14 '25 |
Option Exercise |
0.00 |
8,334 |
0 |
203,761 |
| Bellemin Jean-Marc | Chief Financial Officer |
Mar 03 '25 |
Option Exercise |
0.00 |
58,590 |
0 |
87,938 |
| BILINSKY IGOR | Chief Operating Officer |
Mar 03 '25 |
Option Exercise |
0.00 |
62,106 |
0 |
120,880 |
1.86%
1.98%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):